Corcept Therapeutics ( (CORT) ) just unveiled an announcement.
On February 26, 2025, Corcept Therapeutics announced its financial results for the fourth quarter and full year 2024, reporting a 40% increase in revenue to $675 million and a 33% rise in net income to $141.2 million compared to 2023. The company highlighted significant progress in its clinical development programs, including the submission of a New Drug Application for relacorilant for hypercortisolism and promising results from various studies, positioning relacorilant as a potential new standard of care. The announcement underscores Corcept’s strong financial performance and strategic advancements in its clinical pipeline, which could enhance its market position and impact stakeholders positively.
More about Corcept Therapeutics
Corcept Therapeutics Incorporated is a commercial-stage company focused on the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS, and liver disease. Corcept introduced Korlym, the first FDA-approved medication for hypercortisolism, in February 2012 and is headquartered in Redwood City, California.
YTD Price Performance: 22.53%
Average Trading Volume: 868,188
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $6.42B
See more data about CORT stock on TipRanks’ Stock Analysis page.